Influence of ovarian function supression on quality of life in breast cancer survivors during adjuvant endocrine therapy. (CROSBI ID 737282)
Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Dedić Plavetić, Natalija ; Dugonjić Okroša, Ana ; Silovski, Tajana ; Jović Zlatović, Josipa ; Jajac Bručić, Lana ; Skelin, Marko ; Mucalo, Iva
engleski
Influence of ovarian function supression on quality of life in breast cancer survivors during adjuvant endocrine therapy.
Adding ovarian function suppression to adjuvant endocrine therapy (AET) lowers the disease recurrence rates among premenopausal women with hormone receptor-positive (HR+) early breast cancer (EBC). However, a detrimental effect on endocrine symptoms burden (ESB) is expected. Therefore, this study aimed to investigate differences in Quality of life (QoL) and endocrine symptoms in premenopausal women prescribed AET, with/without gonadotropin- releasing hormone agonist (GnRH).This study showed that GnRH+AI in premenopausal women with HR+ EBC results in greater ESB and lower QoL compared to patients treated with TAM or GnRH+TAM. Therefore, interventions helping decrease the ESB in patients treated with AI+GnRH should be explored and developed to help patients adhere to and persist in AET.
early breast cancer (EBC), ovarian function suppression, adjuvant endocrine therapy
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
560
2023.
nije evidentirano
objavljeno
10.1200/JCO.2023.41.16_suppl.560
Podaci o matičnoj publikaciji
Journal of clinical oncology
0732-183X
1527-7755
Podaci o skupu
ASCO 2023 American Society of Clinical Oncology Annual Meeting
poster
02.06.2023-06.06.2023
Chicago (IL), Sjedinjene Američke Države
Povezanost rada
Kliničke medicinske znanosti